These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 17369863

  • 1. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, Aoki K, Kato K, Nonami A, Kamimura T, Arima F, Takenaka K, Harada N, Fukuda T, Hayashi S, Ohno Y, Eto T, Harada M, Nagafuji K.
    Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
    [Abstract] [Full Text] [Related]

  • 2. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
    Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K, Sakai T, Kumano K, Obara M, Ikeda H, Koike T.
    Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
    [Abstract] [Full Text] [Related]

  • 3. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
    Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):79-85. PubMed ID: 19647953
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec 01; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 5. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May 01; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 6. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C.
    Transfusion; 2007 Aug 01; 47(8):1447-54. PubMed ID: 17655589
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug 01; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 8. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.
    Imamura T, Yoshihara T, Morimoto A, Ishida H, Sugimoto T, Imashuku S.
    Pediatr Hematol Oncol; 2006 Aug 01; 23(1):19-24. PubMed ID: 16326408
    [Abstract] [Full Text] [Related]

  • 9. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec 01; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 10. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M.
    Bone Marrow Transplant; 2004 Jul 01; 34(2):175-9. PubMed ID: 15170171
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
    Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B.
    Bone Marrow Transplant; 2009 Jan 01; 43(2):101-5. PubMed ID: 18794865
    [Abstract] [Full Text] [Related]

  • 12. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N, Ishibashi K, Uno H, Hino N.
    Gan To Kagaku Ryoho; 2002 Dec 01; 29(13):2569-72. PubMed ID: 12506485
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
    Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, Huber C, Derigs HG.
    Bone Marrow Transplant; 2002 May 01; 29(9):769-75. PubMed ID: 12040475
    [Abstract] [Full Text] [Related]

  • 14. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.
    Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL.
    Bone Marrow Transplant; 2003 Jul 01; 32(2):139-43. PubMed ID: 12838277
    [Abstract] [Full Text] [Related]

  • 15. Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma.
    Goto H, Nishio M, Endo T, Sato N, Koizumi K, Fujimoto K, Sakai T, Kumano K, Obara M, Koike T.
    Eur J Haematol; 2005 Jun 01; 74(6):526-8. PubMed ID: 15876258
    [Abstract] [Full Text] [Related]

  • 16. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
    Clin Cancer Res; 2009 Mar 15; 15(6):2107-15. PubMed ID: 19276283
    [Abstract] [Full Text] [Related]

  • 17. [Effective combined modality therapy for a patient with primary adrenal lymphoma].
    Shirao S, Kuroda H, Kida M, Watanabe H, Matsunaga T, Niitsu Y, Konuma Y, Hirayama Y, Kohda K.
    Rinsho Ketsueki; 2006 Mar 15; 47(3):204-9. PubMed ID: 16629485
    [Abstract] [Full Text] [Related]

  • 18. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma.
    Neumann F, Harmsen S, Martin S, Kronenwett R, Kondakci M, Aivado M, Germing U, Haas R, Kobbe G.
    Ann Hematol; 2006 Aug 15; 85(8):530-4. PubMed ID: 16639571
    [Abstract] [Full Text] [Related]

  • 19. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
    Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, Saal R, Gill D, Prince HM, Marlton P, Mollee P.
    Hematol Oncol; 2006 Sep 15; 24(3):159-63. PubMed ID: 16775841
    [Abstract] [Full Text] [Related]

  • 20. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C.
    Br J Haematol; 2008 Dec 15; 143(5):607-21. PubMed ID: 18950460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.